COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effects of Transdermal Scopolamine on Occupational Performance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00374478
Recruitment Status : Completed
First Posted : September 11, 2006
Last Update Posted : April 9, 2007
Centers for Disease Control and Prevention
Information provided by:
Boston University

Brief Summary:
The purpose of this study is to determine the effects of Transdermal scopolamine vs. placebo on ship navigation performance under simulated heavy sea conditions.

Condition or disease Intervention/treatment Phase
Motion Sickness Drug: Scopolamine Phase 2

Detailed Description:
Our study proposes to use a randomized crossover placebo controlled design to test the effects of transdermal scopolamine vs. placebo on simulated ship navigation performance under conditions of heavy seas. We hypothesize that mariners will experience a greater decrement in navigational performance in the placebo condition vs. transdermal scopolamine, when faced with simulated heavy seas. Study staff will apply the transdermal scopolamine patch or placebo patch, 8 hours prior to performance assessment. Participants will surrender car keys and will agree stay on the Kalmar Maritime Campus until they are dismissed from the study. A study nurse and/or study physician will be on call from the time of patch application until study participants are dismissed from the study. Eight hours following patch application participants will perform navigation tasks, under stormy weather conditions, in the bridge simulation lab at Kalmar Maritime Academy. Participants will repeat the protocol one week later under the opposite dosing condition. This study will be conducted at the Kalmar Maritime Academy, Kalmar, Sweden.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Effects of Transdermal Scopolamine on Occupational Performance
Study Start Date : April 2005
Actual Study Completion Date : April 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Motion Sickness

Primary Outcome Measures :
  1. simulated ship navigation performance eight hours following Transdermal scopolamine application

Secondary Outcome Measures :
  1. effectiveness of psychomotor vigilance testing as a fitness-for-duty test

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 20-60 years of age;
  • English speaking;
  • Marine cadets and officers with ship handling experience who volunteer for the study and agree to participate in ship simulation familiarization training prior to study commencement;
  • Agree to refrain from alcohol use for 24 hours prior to dosing;
  • Agree to stay on Kalmar Maritime Campus after scopolamine or placebo drug patch is applied and until study staff approves dismissal;
  • Agree to remain at study site until passing sobriety test and dry mouth assessment;
  • Agree to refrain from driving and operating heavy machinery after patch is applied and for 24 hours following patch removal;
  • Agree to refrain from alcohol use 24 hours following patch removal at Sessions Two and Three;
  • Agree to surrender car keys upon arrival at study site;
  • Agree to receive a cab ride home from study;
  • Females who are not pregnant as measured by a home pregnancy test prior to application of Transdermal scopolamine;
  • Females who are using reliable birth control, per self report, not taking prescription or non prescription drugs contraindicated for Transdermal scopolamine use;
  • Must weigh between 130 ( 58.9 7kgs)-260( 117.93 kgs) pounds;
  • Must score less than a 5 on the Short Version- Michigan Alcohol Screening Test;
  • No history of medical conditions contraindicated for Transdermal scopolamine use.

Exclusion Criteria:

  • Individuals who are under 20 years of age or older than 60;
  • Non-English speaking;
  • Females who are pregnant (as measured by EPT pregnancy test prior to application of Transdermal scopolamine);
  • Females who are not using reliable birth control, per to self report;
  • A score of 5 or more on the SMAST (Short Version- Michigan Alcohol Screening Test);
  • Reported use of recreational drugs;
  • Reported history of treatment for alcohol or substance abuse;
  • Currently taking prescription or non-prescription medications contraindicated for use with Transdermal scopolamine as per Physician's Desk Reference (including sedatives, tranquilizers, belladonna alkaloids, antihistamines, tricyclic antidepressants, and muscle relaxants);
  • Reported history of medical conditions contraindicated for Transdermal scopolamine use (including pyloric obstruction, urinary bladder neck obstruction, impaired liver or kidney function, glaucoma, heart condition, obstructions to the stomach or intestines, prostrate enlargement, seizure history or psychosis);
  • Participants weighing less than 130 lbs ( 58.9 7kg) and greater than 260( 117.93 kg);
  • Allergic to adhesive materials; alcohol consumption 24 hours prior to dosing.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00374478

Layout table for location information
Kalmar Maritime Academy
Kalmar, Sweden, SE-391 82
Sponsors and Collaborators
Boston University
Centers for Disease Control and Prevention
Layout table for investigator information
Principal Investigator: Jonathan Howland, Ph.D., MPH Boston University
Layout table for additonal information Identifier: NCT00374478    
Other Study ID Numbers: CDC R49/CCR115279-5
First Posted: September 11, 2006    Key Record Dates
Last Update Posted: April 9, 2007
Last Verified: April 2007
Keywords provided by Boston University:
Task performance and analysis
Psychomotor vigilance test
Additional relevant MeSH terms:
Layout table for MeSH terms
Motion Sickness
Butylscopolammonium Bromide
Adjuvants, Anesthesia
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists